TALAPRO-2 and First-Line mCRPC Treatment: Insights on OS Benefits and Treatment Sequencing
TALAPRO-2 and First-Line mCRPC Treatment: Insights on OS Benefits and Treatment Sequencing

Alan Tan, MD, Vanderbilt University Medical Center, shares key insights from the TALAPRO-2 trial, discussing the overall survival benefit of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.

He explores the synergy between PARP inhibitors and ARSIs, the role of HRR testing in patient selection, and how liquid biopsies may improve treatment personalization. Dr. Tan also examines the impact of this combination on treatment sequencing, toxicity management, and evolving therapeutic strategies, including chemotherapy, PSMA-targeted therapies, and emerging clinical trials.

Advertisement

Latest News

Patient Perceptions of Germline Genetic Testing Benefits for Prostate Cancer
Patient Perceptions of Germline Genetic Testing Benefits for Prostate Cancer
Emily MenendezProstate Cancer Diagnostics | March 13, 2025
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Pioneering Advances in Bladder Cancer: New Drug Classes, Biomarkers, and Treatment Models
Pioneering Advances in Bladder Cancer: New Drug Classes, Biomarkers, and Treatment Models
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
Utility of ctDNA, Overcoming Barriers to Multidisciplinary Care in Community, Academic Settings
Utility of ctDNA, Overcoming Barriers to Multidisciplinary Care in Community, Academic Settings
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions
Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
Post-EV/Pembro Progression: How Real-World Data is Shaping 2L Treatment Decisions
Post-EV/Pembro Progression: How Real-World Data is Shaping 2L Treatment Decisions
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
Balancing EV/Pembro and Gem/Cis-Nivo: Selecting the Right 1L Therapy for Node-Only Disease
Balancing EV/Pembro and Gem/Cis-Nivo: Selecting the Right 1L Therapy for Node-Only Disease
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
Redefining Urothelial Cancer Care: EV-Pembro, De-Escalation, and Future Strategies
Redefining Urothelial Cancer Care: EV-Pembro, De-Escalation, and Future Strategies
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC
ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC
Emily MenendezRLT | March 7, 2025
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
PSMA-Guided MDT Shows Promise in Oligometastatic RCC
PSMA-Guided MDT Shows Promise in Oligometastatic RCC
Emily MenendezRenal Cell Carcinoma Diagnostics | March 4, 2025
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
COSMIC-021 Expansion Cohort Sheds Light on Efficacy of Cabozantinib, Atezolizumab for aUC
COSMIC-021 Expansion Cohort Sheds Light on Efficacy of Cabozantinib, Atezolizumab for aUC
Emily MenendezAdvanced Urothelial Carcinoma | March 4, 2025
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
Plasma ctDNA Assay Determines Genomic Profile in Patients with Advanced UC
Plasma ctDNA Assay Determines Genomic Profile in Patients with Advanced UC
Emily MenendezUrothelial Carcinoma Diagnostics | February 28, 2025
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
Doublet vs Triplet Therapy for mHSPC: Patient Selection and Treatment Considerations
Doublet vs Triplet Therapy for mHSPC: Patient Selection and Treatment Considerations
Jordan Ciuro, MDmHSPC | February 28, 2025
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Brad McGregor, MDMuscle Invasive Urothelial Carcinoma | August 14, 2024
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Christopher Kane, MDProstate Cancer | June 20, 2024
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and leading in urology.
MoonRISe-1: TAR-210 for Intermediate-Risk NMIBC
MoonRISe-1: TAR-210 for Intermediate-Risk NMIBC
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | May 28, 2024
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Jennifer Miles-Thomas, MD, FPMRS – Spearheading Female Urology, Health, and Innovation
Jennifer Miles-Thomas, MD, FPMRS – Spearheading Female Urology, Health, and Innovation
Jennifer Miles-Thomas, MD, FPMRSAUA 2024 | April 30, 2024
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
RLT
RLT
mHSPC/mCSPC
mHSPC/mCSPC
Renal Cell Carcinoma
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma Diagnostics
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Urothelial Carcinoma
Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma Diagnostics
Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
Dr. Tyler Seibert provides updates from the 2025 APCC Diagnostics conference.
# Posted on March 3, 2025
# Uromigos-Prostate Cancer
Episode 393: ASCO GU 2025 Review Podcast
Episode 393: ASCO GU 2025 Review Podcast
Dr. Silke Gillessen joins the show to discuss some of the top highlights from this year's ASCO GU conference.
# Posted on February 26, 2025
Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC
Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC
Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
# Posted on February 19, 2025
# Uromigos-Kidney Cancer

Conference Coverage

Live meeting highlights

ADAPT-BLADDER Cohort 4: A Phase 1/2 Trial of Durvalumab Plus Intravesical Gemcitabine and Docetaxel in BCG-Unresponsive NMIBC
Noah Hahn, MDUrothelial Carcinoma | February 24, 2025
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
View More
Extensive Necrosis as a Prognostic Indicator in mRCC Treated With Deferred Cytoreductive Nephrectomy After ICI Treatment
Daniel Joyce, MDRenal Cell Carcinoma | February 24, 2025
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
View More
ASCO GU Prostate Updates: TALAPRO-2 and Other Considerations
Karine Tawagi, MDProstate Cancer | February 24, 2025
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
View More
ASCO GU Bladder Updates: EV-302, CheckMate 274, and More
Karine Tawagi, MDUrothelial Carcinoma | February 24, 2025
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
View More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |